Stockscreener 앱 받기
1.86
1.59%
-0.03
시간 외 거래:
1.86
전일 마감가:
$1.89
열려 있는:
$1.87
하루 거래량:
92,905
Relative Volume:
0.55
시가총액:
$131.58M
수익:
-
순이익/손실:
$-19.57M
주가수익비율:
-0.5942
EPS:
-3.13
순현금흐름:
$-17.24M
1주 성능:
-5.82%
1개월 성능:
-6.53%
6개월 성능:
+43.08%
1년 성능:
-13.49%
1일 변동 폭
$1.73
$1.98
1주일 범위
$1.54
$1.98
52주 변동 폭
$1.12
$4.20
Inhibikase Therapeutics Inc Stock (IKT) Company Profile
명칭
Inhibikase Therapeutics Inc
전화
678-392-3419
주소
3350 RIVERWOOD PARKWAY SE, SUITE 1900, ATLANTA
IKT을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
IKT
Inhibikase Therapeutics Inc
|
1.86 | 131.58M | 0 | -19.57M | -17.24M | -3.13 |
|
VRTX
Vertex Pharmaceuticals Inc
|
475.49 | 122.87B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
546.39 | 61.76B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
546.22 | 33.66B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
226.28 | 29.70B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
208.31 | 22.92B | 3.81B | -644.79M | -669.77M | -6.24 |
Inhibikase Therapeutics Inc Stock (IKT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-02-12 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
Inhibikase Therapeutics Inc 주식(IKT)의 최신 뉴스
In the wake of Inhibikase Therapeutics, Inc.'s (NASDAQ:IKT) latest US$29m market cap drop, hedge funds owners may be forced to take severe actions - simplywall.st
Hedge funds owners may consider drastic measures as Inhibikase Therapeutics, Inc.'s (NASDAQ:IKT) recent US$29m drop adds to long-term losses - Yahoo Finance
H.C. Wainwright maintains Neutral on Inhibikase Therapeutics stock By Investing.com - Investing.com Canada
H.C. Wainwright maintains Neutral on Inhibikase Therapeutics stock - Investing.com India
HC Wainwright Reaffirms “Neutral” Rating for Inhibikase Therapeutics (NYSE:IKT) - Defense World
Inhibikase Therapeutics' (IKT) Neutral Rating Reaffirmed at HC Wainwright - MarketBeat
Inhibikase Therapeutics Inc. (IKT) reports earnings - Quartz
Inhibikase Therapeutics Announces 2024 Financial Results and Highlights Recent Activity - GlobeNewswire
Inhibikase Secures Future: $110M Funding, FDA Green Light, and New Leadership Fuel Growth - Stock Titan
INHIBIKASE THERAPEUTICS Earnings Preview: Recent $IKT Insider Trading, Hedge Fund Activity, and More - Nasdaq
Inhibikase Therapeutics Inc expected to post a loss of 9 cents a shareEarnings Preview - TradingView
Inhibikase Therapeutics (IKT) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now - Zacks Investment Research
After leaving FDA, Cavazzoni joins Pfizer as CMO - BioCentury
Inhibikase enhances leadership with new appointments By Investing.com - Investing.com Nigeria
Inhibikase Announces Expansion of Senior Leadership Team - GlobeNewswire
Inhibikase Therapeutics, Inc. Announces Management Appointments -February 24, 2025 at 08:00 am EST - Marketscreener.com
Inhibikase Therapeutics Completes Merger with CorHepta Pharmaceuticals - TipRanks
Inhibikase enhances leadership with new appointments - Investing.com
Inhibikase Therapeutics (NYSE:IKT) vs. Windtree Therapeutics (NASDAQ:WINT) Critical Survey - Defense World
Inhibikase Therapeutics Appoints Mark Iwicki as New CEO - TipRanks
Inhibikase Appoints Industry Veteran Mark Iwicki as CEO to Drive Next Stage of Company’s Growth - GlobeNewswire
Major Leadership Shake-up: Pharma Veteran Takes Helm at Inhibikase with $110M War Chest - StockTitan
What is HC Wainwright’s Estimate for IKT Q1 Earnings? - Defense World
HC Wainwright & Co. Downgrades Inhibikase Therapeutics (IKT) - MSN
Inhibikase Therapeutics (NYSE:IKT) Lowered to Neutral Rating by HC Wainwright - MarketBeat
Inhibikase Therapeutics (NYSE:IKT) Cut to Neutral at HC Wainwright - Defense World
HC Wainwright & Co. Downgrades Inhibikase Therapeutics (MUN:IQT0) - Nasdaq
This PPG Industries Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday - Benzinga
HC Wainwright Downgrades Inhibikase Therapeutics to Neutral From Buy -February 12, 2025 at 07:59 am EST - Marketscreener.com
Inhibikase Therapeutics (NYSE:IKT) Stock Price Down 2.5%What's Next? - MarketBeat
Inhibikase Thera falls as risvodetinib development paused - The Pharma Letter
Insiders Enjoy US$1.1m Return After Buying Inhibikase Therapeutics Stock - Simply Wall St
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
Inhibikase Therapeutics stops Parkinson's drug development as it fails to show benefits in study - MSN
Inhibikase Halts Parkinson's Drug Development to Focus on PAH - MSN
Stock market today: Aclarion -99.69%, CARGO Therapeutics -76.31% among biggest losers in early trading - Business Upturn
Inhibikase shelves Parkinson’s asset after Phase 2 flop - Endpoints News
Inhibikase Therapeutics (NYSE:IKT) Shares Down 2.5% – Should You Sell? - Defense World
Inhibikase Therapeutics Regains Compliance with Nasdaq Listing R - GuruFocus.com
Bullish Inhibikase Therapeutics Insiders Loaded Up On US$2.70m Of Stock - Yahoo Finance
Parkinson's Disease Clinical and Non-Clinical Studies, Key - openPR
Top 5 Small-cap Pharma Stocks (Updated January 2025) - Investing News Network
Inhibikase Therapeutics Completes Amendment to Certificate of IncorporationAtlanta, Georgia – Inhibikase Therapeutics, Inc. (NYSE:IKT) recently announced the successful completion of a Special Meeting of Stockholders on January 3, 2025. During this m - Defense World
Inhibikase Therapeutics expands authorized shares - Investing.com India
Inhibikase Therapeutics expands authorized shares By Investing.com - Investing.com Australia
Contrasting CRISPR Therapeutics (NASDAQ:CRSP) & Inhibikase Therapeutics (NYSE:IKT) - Defense World
Inhibikase Therapeutics (NYSE:IKT) Trading 3.4% HigherTime to Buy? - MarketBeat
Inhibikase Therapeutics (NYSE:IKT) Trading 3.4% Higher – Still a Buy? - Defense World
Inhibikase Therapeutics Inc (IKT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Inhibikase Therapeutics Inc 주식 (IKT) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Kush Arvind | Director |
Oct 21 '24 |
Buy |
1.37 |
145,000 |
198,650 |
145,000 |
| Munshi Amit | Director |
Oct 21 '24 |
Buy |
1.37 |
365,000 |
500,050 |
365,000 |
4.35%
10.53%
자본화:
|
볼륨(24시간):